Latest & greatest articles for type 1 diabetes

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on type 1 diabetes or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on type 1 diabetes and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for type 1 diabetes

1. A systematic review of illness perception interventions in type 2 diabetes: Effects on glycaemic control and illness perceptions

Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Review Diabet Med Actions . 2021 Mar;38(3):e14495. doi: 10.1111/dme.14495. Epub 2020 Dec 30. A systematic review of illness perception interventions in type 2 diabetes: Effects on glycaemic control and illness perceptions , , , , Affiliations Expand Affiliations 1 Department of Psychological Medicine, University of Auckland, Auckland (...) Psychol Behav Med. 2020;8(1):329-348. Alyami M, Serlachius A, Mokhtar I, Broadbent E. Illness perceptions, HbA1c, and adherence in Type 2 Diabetes in Saudi Arabia. Patient Prefer Adherence. 2019;13:1839-1850. Broadbent E, Donkin L, Stroh JC. Illness and treatment perceptions are associated with adherence to medications, diet, and exercise in diabetic patients. Diabetes Care. 2011;34(2):338-340. Show all 50 references Publication types Review Actions Related information Grant support LinkOut - more

2021 EvidenceUpdates

2. Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update — The User’s Guide

metformin, SU, dipeptidyl peptidase 4 inhibitors (DPP4i) and insulin. When should initiation of insulin be considered? Symptomatic hyperglycemia and/or metabolic decompensation (e.g. unintentional weight loss) Relative insulin deficiency with severely elevated A1C and fasting glucose, even without symptomatic hyperglycemia and/or metabolic decompensation Unclear diagnosis (i.e. type 1 diabetes or latent autoimmune diabetes in adults [LADA] are being considered) Conception planning or during pregnancy (...) in people with type 1 diabetes who do not have microalbuminuria or hypertension ( ). The impressive cardiorenal benefits of SGLT2i have been most clearly demonstrated in persons with evidence of CV or renal disease : MACE reductions in those with history of ASCVD ( , , ) – but not shown in those without ASCVD ( , ); HHF reductions in persons with ASCVD ( ), reduced EF ( ) or CKD ( ); Reduced renal progression in persons with CKD with proteinuria ( ) or ASCVD ( , ). In persons with type 2 diabetes and CV

2021 Diabetes Canada

3. Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update

recommendations were unanimously approved by the Steering Committee. Figure 1 At diagnosis of type 2 diabetes. Figure 2A Reviewing, adjusting or advancing therapy in type 2 diabetes. Figure 2B Reviewing, adjusting or advancing therapy in type 2 diabetes. Figure 3 Starting or advancing insulin in type 2 diabetes. Table 1 Antihyperglycemic agents for use in type 2 diabetes. Table 2 Major clinical outcome trial characteristics for antihyperglycemic agents since US Food and Drug Administration guidance 2009 (...) Diabetes (SUSTAIN-6) ( ). Similar to the LEADER trial of liraglutide ( ), patients were eligible if they had type 2 diabetes and an A1C of 7% or greater; and were age ≥50 years with established CVD or stage 3 or higher CKD or age ≥60 years with at least 1 CV risk factor (microalbuminuria or proteinuria, hypertension and left ventricular hypertrophy, left ventricular systolic or diastolic dysfunction, or an ankle–brachial index of less than 0.9). SUSTAIN-6 enrolled 3,297 participants with a mean

2021 Diabetes Canada

4. A Validated Prediction Model for End-Stage Kidney Disease in Type 1 Diabetes

A Validated Prediction Model for End-Stage Kidney Disease in Type 1 Diabetes A Validated Prediction Model for End-Stage Kidney Disease in Type 1 Diabetes - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Show account info Close Account Logged in as: username Search: Search Save (...) options Display options Format Share Permalink Copy Page navigation Diabetes Care Actions . 2021 Apr;44(4):901-907. doi: 10.2337/dc20-2586. Epub 2021 Jan 28. A Validated Prediction Model for End-Stage Kidney Disease in Type 1 Diabetes , , , , , , , , , Affiliations Expand Affiliations 1 Steno Diabetes Center Copenhagen, Gentofte, Denmark dorte.vistisen@regionh.dk. 2 Steno Diabetes Center Copenhagen, Gentofte, Denmark. 3 Steno Diabetes Center Aarhus, Aarhus, Denmark. 4 University of Edinburgh

2021 EvidenceUpdates

5. Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes Full Text available with Trip Pro

Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Circulation Actions . 2021 Feb 9;143(6):540-552. doi: 10.1161/CIRCULATIONAHA.120.051898. Epub 2020 Nov 16. Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes , , , , , , , , , , , Affiliations Expand Affiliations 1 National and Kapodistrian University of Athens, School of Medicine, Department of Cardiology, Attikon University Hospital, Greece (...) in treatment effect based on preexisting CVD status. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: . Keywords: cardiovascular disease; chronic kidney disease; clinical trial; finerenone; mineralocorticoid receptor; primary and secondary prevention; type 2 diabetes. Figures Figure 1. Composite cardiovascular outcome. Time to… Figure 1. Composite cardiovascular outcome. Time to first onset of cardiovascular death, nonfatal myocardial infarction,… Figure 1. Composite cardiovascular

2021 EvidenceUpdates

6. Effect of Intensive Urate Lowering With Combined Verinurad and Febuxostat on Albuminuria in Patients With Type 2 Diabetes: A Randomized Trial Full Text available with Trip Pro

Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Am J Kidney Dis Actions . 2020 Oct 29;S0272-6386(20)31072-6. doi: 10.1053/j.ajkd.2020.09.009. Online ahead of print. Effect of Intensive Urate Lowering With Combined Verinurad and Febuxostat on Albuminuria in Patients With Type 2 Diabetes: A Randomized Trial , , , , , , Affiliations Expand Affiliations 1 (...) with hyperuricemia and type 2 diabetes mellitus (T2DM). Study design: Phase 2, multicenter, prospective, randomized, double-blind, parallel-group, placebo-controlled trial. Setting & participants: Patients 18 years or older with hyperuricemia, albuminuria, and T2DM. Intervention: Patients randomly assigned 1:1 to verinurad (9mg) plus febuxostat (80mg) or matched placebo once daily for 24 weeks. Outcomes: The primary end point was change in urinary albumin-creatinine ratio (UACR) from baseline after 12 weeks

2021 EvidenceUpdates

7. Cardiovascular safety of evogliptin in patients with type 2 diabetes: A nationwide cohort study Full Text available with Trip Pro

Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Diabetes Obes Metab Actions . 2021 Jan 27. doi: 10.1111/dom.14330. Online ahead of print. Cardiovascular safety of evogliptin in patients with type 2 diabetes: A nationwide cohort study , , , , , , Affiliations Expand Affiliations 1 School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea. 2 Department of Internal Medicine, Hanyang University Guri Hospital, Guri, Republic of Korea. 3 (...) dipeptidyl peptidase-4 inhibitor (DPP-4i), was associated with an increased risk of cardiovascular events compared with glimepiride in patients with type 2 diabetes (T2D). Methods: We conducted a population-based cohort study using South Korea's nationwide healthcare database from 1 January 2014 to 31 December 2018. We identified a base cohort of patients with T2D who newly initiated metformin monotherapy, from which we identified a study cohort of patients who either added or switched to glimepiride

2021 EvidenceUpdates

8. Efficacy and safety of the glucagon-like peptide-1 receptor agonist oral semaglutide in patients with type 2 diabetes mellitus: A systematic review and meta-analysis

Efficacy and safety of the glucagon-like peptide-1 receptor agonist oral semaglutide in patients with type 2 diabetes mellitus: A systematic review and meta-analysis Efficacy and safety of the glucagon-like peptide-1 receptor agonist oral semaglutide in patients with type 2 diabetes mellitus: A systematic review and meta-analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other (...) for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Diabetes Res Clin Pract Actions . 2021 Feb;172:108656. doi: 10.1016/j.diabres.2021.108656. Epub 2021 Jan 9. Efficacy and safety of the glucagon-like peptide-1 receptor agonist oral semaglutide in patients with type 2 diabetes mellitus: A systematic review and meta

2021 EvidenceUpdates

9. Effects of aerobic training with and without progression on blood pressure in patients with type 2 diabetes: A systematic review with meta-analyses and meta-regressions

Effects of aerobic training with and without progression on blood pressure in patients with type 2 diabetes: A systematic review with meta-analyses and meta-regressions Effects of aerobic training with and without progression on blood pressure in patients with type 2 diabetes: A systematic review with meta-analyses and meta-regressions - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several (...) a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Meta-Analysis Diabetes Res Clin Pract Actions . 2021 Jan;171:108581. doi: 10.1016/j.diabres.2020.108581. Epub 2020 Dec 8. Effects of aerobic training with and without progression on blood pressure in patients with type 2 diabetes: A systematic review

2021 EvidenceUpdates

10. Rapid Changes in Serum Testosterone in Men with Newly Diagnosed Type 2 Diabetes With Intensive Insulin and Metformin

of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Diabetes Care Actions . 2021 Apr;44(4):1059-1061. doi: 10.2337/dc20-1558. Epub 2021 Feb 3. Rapid Changes in Serum Testosterone in Men With Newly Diagnosed Type 2 Diabetes With Intensive Insulin and Metformin , , , , , , , , Affiliations Expand Affiliations 1 Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Jiangsu, China. 2 (...) of metformin on testosterone levels in men with type 2 diabetes mellitus (T2DM). Research design and methods: Seventy men with newly diagnosed drug-naive T2DM and HbA 1c >9.0% (75 mmol/mol) were treated with intensive insulin pump therapy for 5 days to achieve glucose normalization. They were randomized to control (continued on intensive insulin only) and metformin (plus metformin) groups (1:1) for 1 month. Testosterone was measured at baseline, randomization, and after 1-month treatment. Results: Total

2021 EvidenceUpdates

11. Effects of Vitamin D Supplementation on Prevention of Type 2 Diabetes in Patients With Prediabetes: A Systematic Review and Meta-analysis

Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Review Diabetes Care Actions . 2020 Jul;43(7):1650-1658. doi: 10.2337/dc19-1708. Effects of Vitamin D Supplementation on Prevention of Type 2 Diabetes in Patients With Prediabetes: A Systematic Review and Meta-analysis , , , , , , , , , , Affiliations Expand Affiliations 1 West China Hospital, Sichuan University, Chengdu (...) University, Chengdu, Sichuan, China fangfang1057@outlook.com. PMID: 33534730 DOI: Item in Clipboard Review Effects of Vitamin D Supplementation on Prevention of Type 2 Diabetes in Patients With Prediabetes: A Systematic Review and Meta-analysis Yu Zhang et al. Diabetes Care . 2020 Jul . Show details Display options Display options Format Diabetes Care Actions . 2020 Jul;43(7):1650-1658. doi: 10.2337/dc19-1708. Authors , , , , , , , , , , Affiliations 1 West China Hospital, Sichuan University, Chengdu

2021 EvidenceUpdates

12. Effects of mindfulness- and acceptance-based interventions on diabetes distress and glycaemic level in people with type 2 diabetes: Systematic review and meta-analysis

a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Diabet Med Actions . 2021 Apr;38(4):e14525. doi: 10.1111/dme.14525. Epub 2021 Feb 1. Effects of mindfulness- and acceptance-based interventions on diabetes distress and glycaemic level in people with type 2 diabetes: Systematic review and meta-analysis (...) , , Affiliations Expand Affiliation 1 The Nethersole School of Nursing, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China. PMID: 33438251 DOI: Item in Clipboard Effects of mindfulness- and acceptance-based interventions on diabetes distress and glycaemic level in people with type 2 diabetes: Systematic review and meta-analysis Hau Yi Ngan et al. Diabet Med . 2021 Apr . Show details Display options Display options Format Diabet Med Actions . 2021 Apr;38(4):e14525. doi: 10.1111/dme.14525

2021 EvidenceUpdates

13. Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression Full Text available with Trip Pro

Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced (...) (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression , , , , Affiliations Expand Affiliations 1 HUMANITAS Gradenigo, Turin, Italy. 2 Department of Cardiology, Azienda Ospedaliero Universitaria, Sassari, Italy. 3 Laboratory of Diabetes and Metabolic disorders, Department of Medical Sciences, University of Turin, Turin, Italy. PMID: 33373368 PMCID: DOI: Free PMC article Item in Clipboard Meta-Analysis Assessing the risk of ketoacidosis due to sodium-glucose

2021 EvidenceUpdates

14. Results from the Effects of MEtformin on cardiovasculaR function in AdoLescents with type 1 Diabetes (EMERALD) study: A brief report of kidney and inflammatory outcomes Full Text available with Trip Pro

: 31377056 Clinical Trial. References REFERENCES Nadeau KJ, Regensteiner JG, Bauer TA, et al. Insulin resistance in adolescents with type 1 diabetes and its relationship to cardiovascular function. J Clin Endocrinol Metab. 2010;95(2):513-521. . Bjornstad P, Maahs DM, Duca LM, et al. Estimated insulin sensitivity predicts incident micro- and macrovascular complications in adults with type 1 diabetes over 6 years: the coronary artery calcification in type 1 diabetes study. J Diabetes Complications. 2016;30 (...) Results from the Effects of MEtformin on cardiovasculaR function in AdoLescents with type 1 Diabetes (EMERALD) study: A brief report of kidney and inflammatory outcomes Results from the Effects of MEtformin on cardiovasculaR function in AdoLescents with type 1 Diabetes (EMERALD) study: A brief report of kidney and inflammatory outcomes - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several

2021 EvidenceUpdates

15. Efficacy and safety of adding sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline BMI >/=27 kg/m(2) Full Text available with Trip Pro

Efficacy and safety of adding sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline BMI >/=27 kg/m(2) Efficacy and safety of adding sotagliflozin, a dual sodium-glucose co-transporter (SGLT)1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline body mass index ≥ 27 kg/m 2 - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set (...) of adding sotagliflozin, a dual sodium-glucose co-transporter (SGLT)1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline body mass index ≥ 27 kg/m 2 , , , , , , , Affiliations Expand Affiliations 1 Diabetes-Zentrum für Kinder und Judendliche, Kinder- und Jugendkrankenhaus AUF DER BULT, Hannover, Germany. 2 Department of Medicine, University of California San Diego, Veterans Affairs Medical Center, San Diego, California. 3 Taking Control of Your Diabetes, Solana

2021 EvidenceUpdates

16. Fully Closed Loop Glucose Control With a Bihormonal Artificial Pancreas in Adults With Type 1 Diabetes: An Outpatient, Randomized, Crossover Trial

Fully Closed Loop Glucose Control With a Bihormonal Artificial Pancreas in Adults With Type 1 Diabetes: An Outpatient, Randomized, Crossover Trial Fully Closed Loop Glucose Control With a Bihormonal Artificial Pancreas in Adults With Type 1 Diabetes: An Outpatient, Randomized, Crossover Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily (...) new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Diabetes Care Actions . 2021 Jan 4;dc202106. doi: 10.2337/dc20-2106. Online ahead of print. Fully Closed Loop Glucose Control With a Bihormonal Artificial Pancreas in Adults With Type 1 Diabetes

2021 EvidenceUpdates

17. Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF Full Text available with Trip Pro

Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features (...) new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Diabetes Care Actions . 2021 Feb;44(2):586-594. doi: 10.2337/dc20-1675. Epub 2020 Dec 18. Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection

2021 EvidenceUpdates

18. Extended Use of the Control-IQ Closed-Loop Control System in Children With Type 1 Diabetes

Extended Use of the Control-IQ Closed-Loop Control System in Children With Type 1 Diabetes Extended Use of the Control-IQ Closed-Loop Control System in Children With Type 1 Diabetes - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. National Institutes of Health National Library (...) Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Diabetes Care Actions . 2021 Feb;44(2):473-478. doi: 10.2337/dc20-1729. Epub 2020 Dec 21. Extended Use of the Control-IQ Closed-Loop Control System in Children With Type 1 Diabetes , , , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Jaeb Center for Health Research, Tampa, FL. 2 Barbara Davis Center

2021 EvidenceUpdates

19. Effects of Vitamin C Supplementation on Glycemic Control and Cardiovascular Risk Factors in People With Type 2 Diabetes: A GRADE-Assessed Systematic Review and Meta-analysis of Randomized Controlled Trials

. Effects of Vitamin C Supplementation on Glycemic Control and Cardiovascular Risk Factors in People With Type 2 Diabetes: A GRADE-Assessed Systematic Review and Meta-analysis of Randomized Controlled Trials , , Affiliations Expand Affiliations 1 School of Exercise and Nutrition Sciences, Deakin University, Melbourne, Victoria, Australia s.mason@deakin.edu.au. 2 Institute for Physical Activity and Nutrition, School of Exercise and Nutrition Sciences, Deakin University, Geelong, Victoria, Australia. PMID (...) : 33472962 DOI: Item in Clipboard Review Effects of Vitamin C Supplementation on Glycemic Control and Cardiovascular Risk Factors in People With Type 2 Diabetes: A GRADE-Assessed Systematic Review and Meta-analysis of Randomized Controlled Trials Shaun A Mason et al. Diabetes Care . 2021 Feb . Show details Display options Display options Format Diabetes Care Actions . 2021 Feb;44(2):618-630. doi: 10.2337/dc20-1893. Authors , , Affiliations 1 School of Exercise and Nutrition Sciences, Deakin University

2021 EvidenceUpdates

20. A 52-week randomized controlled trial of ipragliflozin or sitagliptin in type 2 diabetes combined with metformin: The N-ISM study Full Text available with Trip Pro

, Kyoto, Japan. PMID: 33416200 DOI: Item in Clipboard A 52-week randomized controlled trial of ipragliflozin or sitagliptin in type 2 diabetes combined with metformin: The N-ISM study Masaru Kitazawa et al. Diabetes Obes Metab . 2021 Mar . Show details Display options Display options Format Diabetes Obes Metab Actions . 2021 Mar;23(3):811-821. doi: 10.1111/dom.14288. Epub 2021 Jan 8. Authors , , , , , , , , , , , , , Affiliations 1 Department of Internal Medicine, Niigata University Faculty (...) A 52-week randomized controlled trial of ipragliflozin or sitagliptin in type 2 diabetes combined with metformin: The N-ISM study A 52-week randomized controlled trial of ipragliflozin or sitagliptin in type 2 diabetes combined with metformin: The N-ISM study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging

2021 EvidenceUpdates